Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date of Report: March 26, 2026
Principal Executive Office: Marseille, France
Context: This filing incorporates by reference a press release (Exhibit 99.1) dated March 26, 2026, into the company's registration statements on Form F-3 and Form S-8. The filing is signed by Jonathan Dickinson, Chief Executive Officer.
Key Financial Metrics
The provided filing text does not contain specific financial data. It serves as a cover document incorporating a press release by reference. Consequently, the following metrics are not available in the source text:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Material Changes
The filing text does not provide details on material changes versus prior periods. The specific content of the incorporated press release (Exhibit 99.1) is not included in the provided text, only the reference to it.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or unusual items. The press release referenced in Exhibit 99.1 is excluded from the incorporation by reference regarding the quotation from the CEO and webcast links, but the full text of the press release itself is not present in the input.
Investor Verification Checklist
- Verify the full content of Exhibit 99.1 (Press Release dated March 26, 2026) to understand the specific event or announcement triggering this filing.
- Review the incorporated registration statements (Form F-3 File No. 333-276164 and Form S-8 File No. 333-282031) for updated financial context.
- Confirm if the press release contains material non-financial updates, such as clinical trial results or regulatory approvals, which are common for this biopharmaceutical issuer.